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Abstract
Objective:  Cardiovascular complications in Marfan patients 
include progressive aortic root dilation which can precipitate acute 
aortic dissection, ruptured aorta, severe aortic regurgitation, or all 
the aforementioned. Such complications can be fatal and the cause 
of death prior to any surgical intervention. We set out to identify 
the Marfan population in England and Wales and present their 
surgical outcomes. 
Methods: A total of 306 patients with Marfan syndrome who 
underwent aortic root surgery were identified between April 
2007 and March 2013 from NICOR database. We examined the 
perioperative characteristics of such cohort along with in-hospital 
outcomes and survival. 
Results: Root and ascending segment procedures on Marfan 
patients performed in 3.3% of the total cohort by NICOR root 
surgery patients. The median reported age was 40 years (IQR = 29-
49 years) and 100 (32.7%) were female. Of the patients analysed, 
17.3% were treated non-electively and 68.6% of them received 
concomitant valve procedure. The in-hospital mortality was 2.0%. 
Reoperation for bleeding was required in 8.2% of patients and 
1.3% of them suffered a cerebrovascular accident (CVA). Mortality 
at 1 year was reported as 5.5%. 
Conclusion: The outcomes of surgery on the root and ascending 
aorta in Marfan patients in the United Kingdom are satisfactory; 
however, the overall complexities of this patient population are not 
well understood and would benefit from further investigations.
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INTRODUCTION
Marfan syndrome (MFS) is an autosomal dominant 
connective tissue disorder with key features that primarily affects 
the cardiovascular system, the eyes and the skeleton[1]. The 
reported birth incidence is estimated to be 1 in 9800 births[2]. It 
is well established that 50 to 80% of such patients will develop 
aortic dilation at some stage of their life[3]. Progressive aortic 
dilatation is often associated with aortic valve incompetence, 
which can lead to acute aortic dissection or even ruptured 
aorta, which can be life-threatening. Due to such predictable 
progression, MFS has been the base for extrapolation of clinical 
findings and daily practice to the thoracic aortic aneurysm that 
could be of different aetiologies[4,5]. 
However, despite advanced understanding of the aetiology 
and pathophysiology of MFS, there is a lack of concrete approach 
in the current surgical management with 100% satisfactory 
outcomes. Indeed, except for modifications in surgical 
approaches and imaging assessments, all the treatment protocols 
that are in place in the current era were initiated between 1960 
and 1970[6]. On the contrary, the surgical recourse and post-
operative screening of susceptible patients meant that we now 
offer patients with MFS broad options to help promote patients’ 
quality of life and ensure long-term survival. It is also important 
to mention that medical therapeutics became a well-established 
avenue to halt progression of the disease. Furthermore, it was 
previously perceived that MFS patients would not be suitable 
59
Brazilian Journal of Cardiovascular Surgery 
Braz J Cardiovasc Surg 2020;35(1):58-64
Service (NHS) numbers directly to the Office for National Statistics 
(ONS) death registry; this office bears all deaths in England and 
Wales. The last follow-up date reported was 30th July 2013. 
Data on the causes of death were not available; however, an 
attempt to find these data through the in-hospital mortality data 
was made through linking patient records directly to the ONS 
registry prior to applying the extraction criteria. 
Additional morbidity data according to NACSA definitions 
is also included in this analysis; these data were collected and 
validated in the same way as the pre-operative and operative data.
Statistical Analysis
Data are summarized in the form of categorical and 
dichotomous variables; Figures 1 and 2 are summarised as event 
absolute number and percentage rate. If the continuous data 
were not normally distributed, then they are summarised as 
median and inter-quartile range (IQR). The number of missing 
data was very low; therefore, the categorical variables were 
recorded together with the baseline category list, while the 
continuous variable data were analysed together with the mean 
value prior to the statistical analysis. 
Kaplan-Meier charts were used to actuarial 3-year survival 
(Figures 1 and 2). The log-rank test was used to assess the 
equivalence of mortality rates between groups. 
Statistical analyses were performed using SAS version 9.3 
(SAS Institute, Cary, NC). In all cases, a P value <0.05 was reported 
as statistically significant.
RESULTS
Characteristics of the Study Population
A total of 9144 patients were extracted from the NACSA 
database who underwent surgery on an aortic segment during 
the reported period of 2007-2013. Of these patients, 306 (3.3%) 
were recorded as having an aetiology of MFS and having a 
procedure on either the aortic root or the ascending aorta. 
However, 50 (16.3%) patients lacked the proper follow-up data in 
terms of mortality and were excluded from this analysis.
The cohort of 306 patients was treated at 38 different cardiac 
surgery, with a total of 106 different cardiac surgeons. The largest 
number of procedures performed by a surgeon during this period 
reported to be 15 patients; however, 50 surgeons (47.2%) operated 
on a single MFS patient. The largest number of procedures 
performed in a single hospital was 24. Tables 1 and 2 show the 
pre-operative and operative characteristics of this cohort. 
The median age reported was 40 years (IQR = 29-49 years), 
and 100 (32.7%) were female. In the cohort, 17.3% of the patients 
were treated on a non-elective base and 61.1% of patients had a 
concomitant valve procedure. 
Twenty-five (8.2%) patients had undergone cardiac surgery 
during a previous hospital admission. Both previous and current 
surgeries for these patients are shown in Table 3. 
Outcomes
The all-cause in-hospital mortality rate for all MFS patients 
undergoing aortic root or ascending aorta surgery was 2.0% (6 
candidates for endovascular approaches to an aortic aneurysm[7]. 
This exception has been challenged, and surgical endovascular 
therapy allowed itself a pace in this connective tissue disease. In 
this study, we wanted to reflect upon the experience of open 
surgical intervention on MFS patients in England and Wales, 
concentrating on procedures involving the root and ascending 
segments of the aorta, and to present the outcomes and results 
which will allow us to assess the current trend and direction of 
surgical correction of thoracic aortic aneurysm disease in this 
entity in the United Kingdom. 
METHODS
NICOR Database Set
Data from the National Institute for Cardiovascular Outcomes 
Research (NICOR) and National Adult Cardiac Surgery Audit (NACSA) 
registry related to cardiac surgery in UK were extracted in November 
2014. Records that were duplicate and in the form of percutaneous 
transcatheter aortic valve implantations were removed. Relevant 
data were cross-checked with each local unit for validation.
The inclusion criteria for this study were: procedures 
performed on the aortic root or ascending aortic parts with 
Marfan syndrome aetiology, performed in England or Wales 
between 1st April 2007 and 31st March 2013.
Baseline and Operative Data
The data collected on each patient included patient pre-
operative characteristics, medical conditions, operative data and 
post-operative outcomes. Pre-operative data included patient 
age, calculated at time of the procedure, patient gender, body 
mass index (BMI), angina classification according to the Canadian 
Cardiovascular Society (CCS), dyspnoea grade (as defined per the 
New York Heart Association – NYHA – grade <III and NYHA grade 
≥III), history of recent myocardial infarction within 90 days of the 
actual surgical intervention, previous cardiac surgery, diabetes 
mellitus, current smoking status, presence of pulmonary disease 
or chronic obstructive pulmonary disease (COPD), hypertension, 
serum creatinine level of >200 μmol/L at time of surgery, any 
previous evidence of severe neurological dysfunction, presence 
of extracardiac arteriopathy, pre-operative heart rhythm, current 
left ventricular ejection fraction (classified as <30 poor, 30-50 
moderate and >50% good), use of IV inotropes pre-operatively, 
presence of preoperative cardiogenic shock, and the operative 
urgency status. Operative data included the performance of 
concomitant revascularization and/or valve procedures, duration 
of aortic cross-clamp and cardiopulmonary bypass times.
Outcome Variables
The primary outcome for this study was the in-hospital 
mortality rate. This is defined as any death that is due to any 
cause (cardiac or non-cardiac) during the same admission for 
cardiac surgery. The secondary outcome was in the form of 
mortality rate at time of at the 3-year period follow-up. 
The in-hospital data were collected by the NACSA clinical 
registry system, while post-discharge survival rate was collected 
through linking patient records through their National Health 
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Fig. 1 – Kaplan-Meier chart showing 3-year survival stratified by the most treated distal aortic segments.
Fig. 2 – Kaplan-Meier chart showing 3-year survival in aortic root +/- ascending aorta surgery, stratified by history of cardiac surgery.
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The advent of composite root replacement, albeit mechanical or 
biological conduit, have promoted the armamentarium we now 
dialect to patients. Despite the cloud surmounting valve-sparing 
interventions and the risk of reoperation for aortic insufficiency, 
currently reported at 1.3% per year[8], centres across the globe 
have reported improved results following valve-sparing root 
replacements in the MFS population[9]. 
Surgical interventions are moving at a much rapid pace 
than the much-debated issues hauling timing of surgery, size, 
diameter, valve morphology and post-operative screening in 
MFS. The Aortic Valve Operative Outcomes in Marfan Patients 
(AVOOMP)[10] study group provided data on 316 patients that 
undergone aortic root replacement between 2005 and 2010. 
Total root replacement was performed in 24% (n=77), circulatory 
patients). No patients suffered paraplegia, 4 (1.3%) patients had 
post-operative CVA and 3 (1.0%) patients had transient ischemic 
attack (TIA). Twenty-five patients (8.2%) had reoperation for 
bleeding or tamponade; 1-year follow-up mortality was 5.5%. 
Table 4 summarises these outcomes. 
Figure 2 shows a survival comparison stratified by patient 
history of previous cardiac operations, demonstrating a 
significant survival benefit for patients undergoing a first-time 
procedure (P<0.001).
DISCUSSION
Elective aortic operations in MFS has improved life 
expectancy, regardless of the form or mode of surgery offered. 




Age at operation (years) 40 (29, 49) 0 (0)
Female gender 100 (32.7) 0 (0)
Body mass index (kg/m2) 24.2 (21.1, 27.8) 5 (1.6)
Angina class IV 9 (2.9) 1 (0.3)
NYHA class ≥III 49 (16.0) 1 (0.3)
Previous Q-wave MI 6 (2.0) 0 (0)
Recent MI (within 90 days) 4 (1.3) 0 (0)
Previous PCI 2 (0.7) 7 (2.3)
Previous cardiac surgery 25 (8.2) 13 (4.3)
Diabetes (diet or insulin controlled) 5 (1.6) 0 (0)
Current smoker 38 (12.4) 7 (2.3)
History of hypertension 116 (37.6) 4 (1.3)
Creatinine >200 μmol/L 0 (0) 19 (6.2)
History of renal dysfunction 0 (0) 2 (0.7)
History of pulmonary disease 19 (6.2) 0 (0)
History of neurological disease 10 (3.3) 3 (1.0)
History of neurological dysfunction 6 (2.0) 2 (0.7)
Peripheral vascular disease 50 (16.3) 0 (0)
Non-sinus heart rhythm 14 (4.6) 10 (3.3)
Triple vessel disease 2 (0.7) 54 (17.7)
Left ventricular ejection fraction 30-50% 34 (11.1) 10 (3.3)
Left ventricular ejection fraction <30% 7 (2.3) 10 (3.3)
Intravenous nitrates or any heparin 10 (3.3) 0 (0)
Intravenous inotropes prior to anaesthesia 3 (1.0) 2 (0.7)
Pre-operative ventilation 4 (1.3) 3 (1.0)
Pre-operative cardiogenic shock 7 (2.3) 2 (0.7)
Continuous variables shown as median (25th percentile, 75th percentile); categorical variables shown as frequency (%).
MI=myocardial infarction; NYHA=New York Heart Association; PCI=percutaneous coronary intervention.
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Elective operation 253 (82.7) 0 (0)
Urgent operation 21 (6.9) 0 (0)
Emergency operation 30 (9.8) 0 (0)
Salvage operation 2 (0.7) 0 (0)
Procedure type
Composite valve graft and coronary reimplantation (modified Bentall or Cabroll) 147 (48.0) 0 (0)
Preservation of native valve and coronary reimplantation 95 (31.0) 0 (0)
Interposition tube graft with/without extension into the arch 36 (11.8) 0 (0)
Tube graft + separate AVR 14 (4.6) 0 (0)
Homograft root replacement 5 (1.6) 0 (0)
Aortic patch graft 4 (1.3) 0 (0)
Reduction aortoplasty 3 (1.0) 0 (0)
Sinus of Valsalva repair 2 (0.7) 0 (0)
Concomitant CABG procedure 20 (6.5) 13 (4.3)
Concomitant valve procedure 210 (68.6) 6 (2.0)
Concomitant 'other' cardiac procedure 70 (22.9) 12 (3.9)
Cardiopulmonary bypass time (mins) 166 (128, 214) 5 (1.6)
Aortic cross-clamp time (mins) 126 (97, 161) 6 (2.0)
AVR=aortic valve replacement; CABG=coronary artery bypass grafting
Table 3. History of previous cardiac operations
Previous cardiac operation 
(n=25)
Previous procedure type
Valve + ascending aorta or aortic arch surgery 12 (48.0)
Isolated valve 6 (24.0)
Isolated ascending aorta or aortic arch surgery 3 (12.0)
Valve + 'other' cardiac procedure 2 (8.0)
Valve + ascending aorta or aortic arch surgery + 'other' cardiac procedure 1 (4.0)
'Other' cardiac procedure 1 (4.0)
Current procedure type
Composite valve graft and coronary reimplantation (modified Bentall or Cabroll) 10 (40.0)
Interposition tube graft with/without extension into the arch 7 (28.0)
Aortic patch graft 3 (12.0)
Preservation of native valve and coronary reimplantation 2 (8.0)
Homograft root replacement 1 (4.0)
Tube graft + separate AVR 1 (4.0)
Reduction aortoplasty 1 (4.0)
AVR=aortic valve replacement
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proportion of composite root repair seen in the results section. In 
a brief overview, conversion rate in the literature from intended 
valve-sparing to total aortic root replacement is at a higher rate 
than the AVOOMP rate of 1:40[8], especially in small series cohort 
with less experienced surgeons. 
The recent revision of the clinical guidelines likely will lead 
to a reduction in the rate of acute aortic root dissections in MFS 
patients. Nevertheless, aortic dissection can occur in the absence 
of any significant or known risk factors. Therefore, improvement 
in long-term prognosis of MFS patients can be achieved more 
accurately through earlier detection of progressed disease by 
the application of the current clinical guidelines, thorough 
assessment and follow-up imaging of the entire aorta, and 
looking into other risk factors that can predispose to aortic 
dissection. However, in the UK there is a lack of centralization 
of expertise and aortic service provision in all of its forms. 
Additionally, surgery on MFS patients is not being practiced 
through a rigorous protocol, which can affect the outcomes 
between high and low-volume surgeons[12-14]. 
Limitations
The retrospective nature of this study is the main limitation of 
this study. The main confounding factors are case selection, lack 
of data for structured referral and long-term follow-up through 
imaging modality to delineate the effect of natural history on 
the aorta. Other confounding factors include delays between 
diagnosis and initiation of treatment, lack of prophylactic 
operation data and referral bias. Furthermore, the direct effect of 
beta-blockers on the growth rate of the aortic root aneurysms has 
not been analysed and, as our cohort were prior to establishing 
such treatment, the results could have been different with the 
inclusion of this analysis. 
CONCLUSION
The nationwide reported results on aortic aneurysm surgery 
in MFS still represent a challenge. The aortic root +/- ascending 
arrest was used in 29%; the median cardiopulmonary bypass 
time was 152 minutes, while the median cross-clamp time was 
115 minutes. Valve-sparing interventions were performed in 
76% of patients (n=239), circulatory arrest was used in 20%; the 
median cardiopulmonary bypass time was 194 minutes, while 
the median cross-clamp time was 156 minutes. Patients that 
underwent root operations were few in number, older in age and 
higher risk patients, which reflects the choice for valve-sparing 
surgery among these surgeons. The reoperation rate among the 
valve-sparing cohort was much higher. Putting all those issues 
aside, it is imperative, regardless of the form of surgery, that an 
operation should be offered to those patient populations to 
avert the detrimental aortic dissection.  
In the UK, we drew conclusions from type A aortic dissection 
on national scale related to surgeon and hospital volume[11]. We 
provided evidence that a mean annual volume of less than four 
cases of type A performed by aortic surgeon is ill-fated. Faced 
with connective tissue disorder patients as in MFS and in centres 
that lack structured aortic referral, resources and concentration 
of aortic expertise, the much-feared MFS population will also 
have an ill fate not only in an emergency dissection setting, but 
also in the elective phase. 
This study revealed that the overall in-hospital mortality rate 
in MFS patients who had aortic root surgery is 2.0%. When we 
zoom in, we find that only a small group of patients, i.e. 31% 
of the whole cohort, had native valve preservation. This surely 
raises a striking question: why is native valve-sparing surgery 
not being performed at much-extended breadth? We have 
no meaningful answer that we could divulge. However, as in 
the AVOOMP study, 2.5% of the cohort had problems during 
valve-sparing procedure, which resulted in conversion to total 
aortic root replacement with a composite graft. However, this 
outcome is not always reported in patients with valve-sparing 
interventions. This might explain the paradox we mentioned 
above as to perhaps surgeons in the UK are attempting the 
native valve preservation procedure explicitly and, due to lack of 
expertise, conversion to composite valve conduit ensue the high 




In-hospital mortality 6 (2.0) 0 (0)
All cause reoperation 29 (9.5) 16 (5.2)
Reoperation for bleeding/tamponade 25 (8.2) 16 (5.2)
Neurological complications
Paraplegia 0 (0) 29 (9.5)
CVA 4 (1.3) 29 (9.5)
TIA 3 (1.0) 29 (9.5)
Post-operative dialysis 4 (1.3) 22 (7.2)
1-year mortality 14/256 (5.5) 50 (16.3)
CVA=cerebrovascular accident; TIA=transient ischemic attack
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aorta outcomes are close to the reported series in the literature. 
We call for an extended multidisciplinary team approach to deal 
with connective tissue disorders related to aortic disease and 
for such cohort to be concentrated through a robust referral 
system to aortic centres that provides a multitude of resources, 
and surgical expertise for aortic surgery in connective tissue 
disorders.
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